Literature DB >> 26222770

Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia.

Corrie Studd1,2, Georgina Cameron1, Lauren Beswick1, Ross Knight3, Christopher Hair3, John McNeil4, Paul Desmond1, Jarrad Wilson1, Wiliam Connell1, Sally Bell1.   

Abstract

BACKGROUND AND AIMS: Regional variations in inflammatory bowel disease (IBD) rates have been observed. Limited epidemiological data are available from Australasia. IBD prevalence rates have never been assessed in an Australian population-based setting. In addition, there are few historical IBD incidence data to allow assessment of rate changes. The aims were to calculate Australia's first population-based IBD prevalence rates, to reassess local IBD incidence rates, and to establish a population-based inception cohort.
METHODS: An observational, prospective population-based epidemiological study was performed to assess IBD prevalence and incidence rates from July 2010 to June 2011 in a geographically defined Australian population (Barwon, Victoria).
RESULTS: There were 1011 prevalent IBD cases identified, representing a crude point prevalence rate of 344.6 per 100,000 on June 30, 2011. Crohn's disease was the most common prevalent subtype. Seventy-one incident cases of IBD were identified, with a crude incidence rate of 24.2 per 100,000. Crohn's disease was again more common. Local incidence rates have not changed between 2007 and the present study. All incident cases were successfully incorporated into an inception cohort.
CONCLUSION: The burden of IBD in our local region is high. Demographic similarities allow these results to be applied to the broader Australian community. We propose that the number of existing and new cases each year in Australia has been previously underestimated. These revised figures will be important when planning the provision of health resources for these patients in the future and when assessing need for research funding priorities.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  IBD; epidemiology; incidence; prevalence

Mesh:

Year:  2016        PMID: 26222770     DOI: 10.1111/jgh.13050

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  8 in total

Review 1.  A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration.

Authors:  P Tavakoli; U Vollmer-Conna; D Hadzi-Pavlovic; M C Grimm
Journal:  Public Health Rev       Date:  2021-05-05

2.  The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada.

Authors:  Keeley L Rose; Philip M Sherman; Jane Cooke-Lauder; Mina Mawani; Eric I Benchimol; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Sanjay K Murthy; Geoffrey C Nguyen; Kate Lee
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

3.  Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

Authors:  Waled Mohsen; Astrid-Jane Williams; Gabrielle Wark; Alexandra Sechi; Jenn-Hian Koo; Wei Xuan; Milan Bassan; Watson Ng; Susan Connor
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742

4.  Addressing pregnancy-related concerns in women with inflammatory bowel disease: Insights from the patient's perspective.

Authors:  Emma K Flanagan; Jacqui Richmond; Alexander J Thompson; Paul V Desmond; Sally J Bell
Journal:  JGH Open       Date:  2020-11-09

5.  Ulcerative Colitis Narrative findings: Australian survey data comparing patient and physician disease management views.

Authors:  Susan J Connor; Alexandra Sechi; Mauricio Andrade; J Jasper Deuring; David Witcombe
Journal:  JGH Open       Date:  2021-08-14

6.  Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis.

Authors:  Kirsten J Coppell; Ciarán P-C Galts; Fokko Y Huizing; Joanna K Norton; Andrew R Gray; Kim Schultz; Catherine E Hobbs; Kristina Aluzaite; Michael Schultz
Journal:  Inflamm Intest Dis       Date:  2018-09-17

7.  Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway.

Authors:  Hui Wang; Shuhua Li; Houzhong Li; Fengxia DU; Jie Guan; Yanmin Wu
Journal:  Iran J Public Health       Date:  2019-07       Impact factor: 1.429

8.  Exosomal CagA from Helicobacter pylori aggravates intestinal epithelium barrier dysfunction in chronic colitis by facilitating Claudin-2 expression.

Authors:  Yinjie Guo; Canxia Xu; Renjie Gong; Tingzi Hu; Xue Zhang; Xiaoran Xie; Jingshu Chi; Huan Li; Xiujuan Xia; Xiaoming Liu
Journal:  Gut Pathog       Date:  2022-03-24       Impact factor: 4.181

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.